Armistice Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Armistice Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,965,000	Closed	-$33.7M	–	177
2021 Q3	$33.7M	Sell	1,965,000 -749,000	-28%	-$13.1M	0.57%	52
2021 Q2	$58.4M	Sell	2,714,000 -1,082,000	-29%	-$19.4M	1.05%	22
2021 Q1	$57M	Sell	3,796,000 -1,603,277	-30%	-$26M	1.31%	22
2020 Q4	$70.9M	Sell	5,399,277 -50,723	-0.9%	-$611K	2.41%	5
2020 Q3	$52.6M	Buy	5,450,000 +650,000	+14%	+$6.95M	1.91%	12
2020 Q2	$54.9M	Buy	4,800,000 +232,000	+5%	+$2.63M	2.41%	8
2020 Q1	$47.3M	Buy	4,568,000 +1,740,000	+62%	+$21.6M	2.93%	5
2019 Q4	$46.4M	Sell	2,828,000 -720,000	-20%	-$10.9M	2.68%	6
2019 Q3	$47.1M	Buy	3,548,000 +390,000	+12%	+$5.44M	3.12%	6
2019 Q2	$44.5M	Buy	+3,158,000	New	+$50.3M	2.81%	5
2018 Q4	–	Sell	-900,000	Closed	-$20.7M	–	97
2018 Q3	$20.7M	Sell	900,000 -1,324,000	-60%	-$27M	1.24%	28
2018 Q2	$42.4M	Sell	2,224,000 -376,000	-14%	-$6.29M	2.77%	6
2018 Q1	$43.8M	Sell	2,600,000 -78,000	-3%	-$1.31M	3.35%	3
2017 Q4	$40.7M	Buy	2,678,000 +1,146,000	+75%	+$17M	4.06%	4
2017 Q3	$27.4M	Sell	1,532,000 -532,000	-26%	-$8.9M	3.23%	4
2017 Q2	$33.6M	Buy	2,064,000 +456,000	+28%	+$6.57M	4.29%	2
2017 Q1	$22.5M	Buy	1,608,000 +1,028,000	+177%	+$14.7M	4.65%	3
2016 Q4	$9.25M	Buy	580,000 +30,000	+5%	+$482K	2.19%	18
2016 Q3	$9.15M	Sell	550,000 -250,000	-31%	-$3.37M	2.94%	8
2016 Q2	$8.95M	Sell	800,000 -800,000	-50%	-$7.75M	3.41%	3
2016 Q1	$13.4M	Sell	1,600,000 -30,000	-2%	-$246K	5.25%	3
2015 Q4	$15.2M	Buy	1,630,000 +870,000	+114%	+$8.68M	5.41%	3
2015 Q3	$8.57M	Sell	760,000 -382,000	-33%	-$4.67M	2.93%	14
2015 Q2	$14.5M	Sell	1,142,000 -1,142,000	-50%	-$12.3M	5.21%	5
2015 Q1	$21.2M	Buy	2,284,000 +1,556,000	+214%	+$17.6M	9.41%	2
2014 Q4	$10.4M	Buy	+728,000	New	+$8.61M	5.01%	3

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Armistice Capital's VNDA Position: Q4 2021 in Review

Armistice Capital sold out of Vanda Pharmaceuticals (VNDA) in Q4 2021, closing a stake of 1,965,000 shares — an estimated $33.7M sold.

Armistice Capital first reported a position in VNDA in Q4 2014 and held it in 26 quarters. The position peaked at $70.9M in Q4 2020. 198 funds tracked by Wall St. Rank hold VNDA as of Q4 2021.

Armistice Capital reported no remaining Vanda Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Armistice Capital sold 1,965,000 Vanda Pharmaceuticals shares in Q4 2021, an estimated $33.7M.
Armistice Capital first reported a position in Vanda Pharmaceuticals in Q4 2014 and held it in 26 quarters.
Armistice Capital's Vanda Pharmaceuticals position peaked at $70.9M in Q4 2020.
198 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2021.

Based on Armistice Capital's 13F filing for Q4 2021, filed 14 Feb 2022.